Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions

NCT00091689 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00091689
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00091689 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Efficacy of an Immune Response Modifier to Treat Inoperable Advanced Melanoma Skin Lesions
Lead sponsor
Pfizer
Phase
Phase 1
Overall status
Completed
Start date
September 30, 2004
Completion date
January 31, 2006
Enrollment
Not reported
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma